Compare INNV & SANA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INNV | SANA |
|---|---|---|
| Founded | 2007 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Nursing Services | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.4B |
| IPO Year | 2021 | 2021 |
| Metric | INNV | SANA |
|---|---|---|
| Price | $8.92 | $3.14 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | $7.00 | ★ $7.50 |
| AVG Volume (30 Days) | 397.5K | ★ 1.9M |
| Earning Date | 01-01-0001 | 06-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 17.24 |
| EPS | ★ 0.14 | N/A |
| Revenue | ★ $853,699,000.00 | N/A |
| Revenue This Year | $12.82 | N/A |
| Revenue Next Year | $9.22 | N/A |
| P/E Ratio | $67.57 | ★ N/A |
| Revenue Growth | ★ 11.76 | N/A |
| 52 Week Low | $2.60 | $1.27 |
| 52 Week High | $10.69 | $6.55 |
| Indicator | INNV | SANA |
|---|---|---|
| Relative Strength Index (RSI) | 56.05 | 28.61 |
| Support Level | $5.01 | $2.85 |
| Resistance Level | $9.18 | $3.24 |
| Average True Range (ATR) | 0.77 | 0.26 |
| MACD | -0.02 | -0.07 |
| Stochastic Oscillator | 39.59 | 4.71 |
InnovAge Holding Corp is a healthcare delivery platform comprising multiple participants focused on providing all-inclusive, capitated care to high-cost seniors, many of whom are dual-eligible. Its programs are designed to address two of the pressing challenges facing the U.S. healthcare industry: rising costs and poor outcomes. The purpose of the participant-centered care delivery approach is to improve the quality of care participants receive, while keeping them in their homes for as long as possible and reducing the overutilization of high-cost care settings, such as hospitals and nursing homes. The company manages its business as one reportable segment, PACE.
Sana Biotechnology Inc is a biotechnology company. The company develops engineered cells as medicines and therapies to treat diseases. It is engaged in developing cell engineering programs for across a broad array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune, and central nervous system (CNS) disorders, among others. Its pipeline of product candidates is comprised of SC291, SC262, SC255, UP421 and others.